Correlation Between Eliem Therapeutics and Reviva Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Eliem Therapeutics and Reviva Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eliem Therapeutics and Reviva Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Eliem Therapeutics and Reviva Pharmaceuticals Holdings, you can compare the effects of market volatilities on Eliem Therapeutics and Reviva Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eliem Therapeutics with a short position of Reviva Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eliem Therapeutics and Reviva Pharmaceuticals.

Diversification Opportunities for Eliem Therapeutics and Reviva Pharmaceuticals

0.38

Correlation Coefficient

Eliem Therapeutics  Reviva Pharmaceuticals

Weak diversification

The 3 months correlation between Eliem and Reviva is 0.38. Overlapping area represents the amount of risk that can be diversified away by holding Eliem Therapeutics and Reviva Pharmaceuticals Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Reviva Pharmaceuticals and Eliem Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eliem Therapeutics are associated (or correlated) with Reviva Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Reviva Pharmaceuticals has no effect on the direction of Eliem Therapeutics i.e., Eliem Therapeutics and Reviva Pharmaceuticals go up and down completely randomly.

Pair Corralation between Eliem Therapeutics and Reviva Pharmaceuticals

Given the investment horizon of 90 days Eliem Therapeutics is expected to under-perform the Reviva Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Eliem Therapeutics is 1.45 times less risky than Reviva Pharmaceuticals. The stock trades about -0.24 of its potential returns per unit of risk. The Reviva Pharmaceuticals Holdings is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  124.00  in Reviva Pharmaceuticals Holdings on September 1, 2024 and sell it today you would earn a total of  0.00  from holding Reviva Pharmaceuticals Holdings or generate 0.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	98.41%
Values	Daily Returns

Eliem Therapeutics  vs.  Reviva Pharmaceuticals Holding

Eliem Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Eliem Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Reviva Pharmaceuticals

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Reviva Pharmaceuticals Holdings are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Reviva Pharmaceuticals demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Eliem Therapeutics and Reviva Pharmaceuticals

The main advantage of trading using opposite Eliem Therapeutics and Reviva Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eliem Therapeutics position performs unexpectedly, Reviva Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Reviva Pharmaceuticals will offset losses from the drop in Reviva Pharmaceuticals' long position.

The idea behind Eliem Therapeutics and Reviva Pharmaceuticals Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.